ipilimumab,cabozantinib,nivolumab
exelixis,bms
['cabozantinib', 'vance', 'nivolumab', 'ipilimumab', 'cosmic-313', 'nivo']
cosmic-313 is the first study to combine cabozantinib (tki) with nivolumab and ipilimumab (immunotherapies) and compare it to ipilimumab plus nivolumab for the treatment of people with intermediate or poor risk advanced #kidneycancer
read more: 
Patients first & foremost: the only UK patient led, patient managed kidney cancer charity; supporting patients, carers and their families since 2006